, Singapore

Daily Markets Briefing: STI up 0.2%

Immediate support still pegged at the 3,265 mark.

OCBC Investment Research noted:

The continued retreat by the US indices overnight could keep the local bourse on the back-foot this morning.

Despite registering a mild 0.2% gain yesterday, the STI is clearly having difficulties overcoming its 2-week downtrend resistance line at the moment.

Going forward, the index is likely to continue drifting just below this downtrend resistance with the immediate support still pegged at the 3,265 minor trough.

Beyond that, the next base lies at the 3,240 key resistance-turned-support. On the upside, the immediate resistance is marked at the 3,300 psychological hurdle and downtrend resistance, with the next obstacle lying at the 3,315 recent peak.

IG Markets Singapore said:

The STI closed slightly higher yesterday +4pts to 3294. We expect the STI to open mostly unchanged. 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare